雷迪帕韦-索磷布韦治疗丙型肝炎与葡萄膜炎的关联
该病例系列纳入2015年6月至2017年6月在城区学术机构接受雷迪帕韦-索磷布韦治疗丙型肝炎、并出现后葡萄膜炎体征和症状的6例患者,均为12周疗程。作者认为该治疗可能与一种不同于干扰素视网膜病变的轻度后葡萄膜炎相关,但尚不能视为因果关系,目前也无法量化关联。
要点
- 6例患者均在雷迪帕韦-索磷布韦治疗丙型肝炎后出现后葡萄膜炎,全身葡萄膜炎检查均为阴性。
- 主要眼部表现为周边血管炎(9眼中8眼)、视乳头炎(9眼中7眼)和黄斑囊样水肿(9眼中6眼)。
- 作者强调这些发现不能被视为因果关系,目前无法量化关联。
核心结论
- 在接受雷迪帕韦-索磷布韦治疗丙型肝炎的患者中,该治疗似乎与一种不同于干扰素视网膜病变的轻度后葡萄膜炎相关。
- 鉴于接受该药治疗的患者数量庞大,这些发现不能视为因果关系,目前也无法量化关联。
研究设计与样本
- 病例系列,纳入2015年6月至2017年6月在城区学术机构接受雷迪帕韦-索磷布韦治疗丙型肝炎、已知出现后葡萄膜炎体征和症状的患者。
- 所有患者均接受雷迪帕韦-索磷布韦治疗丙型肝炎,总疗程12周;除1例外,其余患者就诊前均已完成治疗。
- 共收集6例患者数据,中位年龄64.5岁(范围54-72岁);5例男性;4例白人,2例非洲裔美国人。
主要发现
- 从开始治疗到就诊的平均(SD)时间为8.8(5.5)个月。
- 6例患者中3例双眼受累(共9眼);受累眼中位就诊视力为20/40(范围20/20-20/70)。
- 5例表现为视物模糊,1例表现为旁中心暗点。
- 主要眼部表现为周边血管炎(9眼中8眼)、视乳头炎(9眼中7眼)和黄斑囊样水肿(9眼中6眼)。
- 中位随访8个月(范围4-13个月),中位最终视力为20/40(范围20/20-20/200)。
关键数值与推荐
- 所有患者全身葡萄膜炎检查均为阴性。
- 所有患者雷迪帕韦-索磷布韦治疗丙型肝炎总疗程为12周。
- 受累眼中位就诊视力20/40(范围20/20-20/70),中位最终视力20/40(范围20/20-20/200)。
临床怎么用
- 对接受雷迪帕韦-索磷布韦治疗丙型肝炎后出现视物模糊或旁中心暗点的患者,应考虑后葡萄膜炎的可能并进行眼科评估。
- 眼底检查需关注周边血管炎、视乳头炎和黄斑囊样水肿等体征。
- 向患者说明目前仅为关联信号、不能视为因果关系,尚需进一步研究量化风险。
局限性
- 为病例系列,样本量小(6例患者、9眼),无对照人群。
- 作者明确指出这些发现不能视为因果关系,目前无法量化关联。
- 原文未报告系统性葡萄膜炎检查的具体项目及治疗干预细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Ledipasvir-sofosbuvir has become the current standard of care for hepatitis C since its release in 2014. Therefore, potential adverse effects are important to identify. OBJECTIVE: To report findings of uveitis after treatment with ledipasvir-sofosbuvir for hepatitis C. DESIGN, SETTING, AND PARTICIPANTS: This case series includes patients treated in an urban academic setting with ledipasvir-sofosbuvir for hepatitis C from June 2015 to June 2017 who are known to have developed signs and symptoms of posterior uveitis. EXPOSURES: All patients had been treated with ledipasvir-sofosbuvir for hepatitis C for a total of 12 weeks. All patients but 1 had finished treatment prior to presentation. MAIN OUTCOMES AND MEASURES: Signs of posterior uveitis on ophthalmic testing. RESULTS: Data were collected from 6 patients (median age, 64.5 [range, 54-72] years). Five patients were male; 4 were white, and 2 were African American. The mean (SD) time between beginning of treatment and presentation was 8.8 (5.5) months. Both eyes were affected in 3 of the 6 patients (total, 9 eyes). The median presenting visual acuity in affected eyes was 20/40 (range, 20/20-20/70). All patients had a negative systemic uveitis workup. Five patients presented with blurred vision, and 1 had a paracentral scotoma. The main ocular findings were peripheral vasculitis (in 8 of 9 eyes), papillitis (in 7 of 9 eyes), and cystoid macular edema (in 6 of 9 eyes). The median follow-up was 8 (range, 4-13) months. The median final visual acuity was 20/40 (range, 20/20-20/200). CONCLUSIONS AND RELEVANCE: In these patients, it appears that treatment with ledipasvir-sofosbuvir for hepatitis C was associated with a mild posterior uveitis different than interferon retinopathy. Given the large number of patients treated with ledipasvir-sofosbuvir, these findings cannot be considered causative, and an association cannot be quantified at this time.
引用
- Padidam S, Burke MT, Apple DB, et al. Association of Ledipasvir-Sofosbuvir Treatment With Uveitis in Patients Treated for Hepatitis C. JAMA Ophthalmol. 2019. PMID: 30920588. doi:10.1001/jamaophthalmol.2019.0374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。